Japan · Delayed Price · Currency is JPY Sumitomo Pharma Statistics
Total Valuation
Sumitomo Pharma has a market cap or net worth of JPY 552.23 billion. The enterprise value is 841.02 billion.
| Market Cap | 552.23B |
| Enterprise Value | 841.02B |
Important Dates
The last earnings date was Thursday, July 31, 2025.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Sumitomo Pharma has 397.29 million shares outstanding.
| Current Share Class | 397.29M |
| Shares Outstanding | 397.29M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 16.60% |
| Float | 180.16M |
Valuation Ratios
The trailing PE ratio is 29.21 and the forward PE ratio is 10.40. Sumitomo Pharma's PEG ratio is 1.02.
| PE Ratio | 29.21 |
| Forward PE | 10.40 |
| PS Ratio | 1.33 |
| PB Ratio | 3.13 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.39 |
| P/OCF Ratio | 13.35 |
| PEG Ratio | 1.02 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.14, with an EV/FCF ratio of 24.96.
| EV / Earnings | 44.49 |
| EV / Sales | 2.02 |
| EV / EBITDA | 14.14 |
| EV / EBIT | 23.61 |
| EV / FCF | 24.96 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 1.75.
| Current Ratio | 1.11 |
| Quick Ratio | 0.46 |
| Debt / Equity | 1.75 |
| Debt / EBITDA | 5.07 |
| Debt / FCF | 9.18 |
| Interest Coverage | 0.93 |
Financial Efficiency
Return on equity (ROE) is 11.21% and return on invested capital (ROIC) is 4.48%.
| Return on Equity (ROE) | 11.21% |
| Return on Assets (ROA) | 2.90% |
| Return on Invested Capital (ROIC) | 4.48% |
| Return on Capital Employed (ROCE) | 7.41% |
| Revenue Per Employee | 108.60M |
| Profits Per Employee | 4.93M |
| Employee Count | 3,832 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.57 |
Taxes
| Income Tax | -6.57B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +175.31% in the last 52 weeks. The beta is 0.52, so Sumitomo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +175.31% |
| 50-Day Moving Average | 1,056.58 |
| 200-Day Moving Average | 762.13 |
| Relative Strength Index (RSI) | 65.92 |
| Average Volume (20 Days) | 10,054,360 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sumitomo Pharma had revenue of JPY 416.16 billion and earned 18.90 billion in profits. Earnings per share was 47.58.
| Revenue | 416.16B |
| Gross Profit | 253.56B |
| Operating Income | 37.16B |
| Pretax Income | 12.34B |
| Net Income | 18.90B |
| EBITDA | 61.01B |
| EBIT | 37.16B |
| Earnings Per Share (EPS) | 47.58 |
Balance Sheet
The company has 20.45 billion in cash and 309.25 billion in debt, giving a net cash position of -288.79 billion or -726.91 per share.
| Cash & Cash Equivalents | 20.45B |
| Total Debt | 309.25B |
| Net Cash | -288.79B |
| Net Cash Per Share | -726.91 |
| Equity (Book Value) | 176.23B |
| Book Value Per Share | 443.59 |
| Working Capital | 25.03B |
Cash Flow
In the last 12 months, operating cash flow was 41.36 billion and capital expenditures -7.67 billion, giving a free cash flow of 33.69 billion.
| Operating Cash Flow | 41.36B |
| Capital Expenditures | -7.67B |
| Free Cash Flow | 33.69B |
| FCF Per Share | 84.80 |
Margins
Gross margin is 60.93%, with operating and profit margins of 8.93% and 4.54%.
| Gross Margin | 60.93% |
| Operating Margin | 8.93% |
| Pretax Margin | 2.97% |
| Profit Margin | 4.54% |
| EBITDA Margin | 14.66% |
| EBIT Margin | 8.93% |
| FCF Margin | 8.10% |
Dividends & Yields
Sumitomo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.02% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 3.42% |
| FCF Yield | 6.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sumitomo Pharma has an Altman Z-Score of 1.16 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.16 |
| Piotroski F-Score | 7 |